Cargando…

Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma

The present study aimed to investigate the curative effect of high-dose methotrexate (HD-MTX) combined with teniposide (Vm26) vs. HD-MTX alone in the treatment of primary central nervous system lymphoma (PCNSL), in order to provide data for assisting decisions associated with clinical treatment. Dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yi-Xia, Huang, Yan, Xu, Xiao-Ping, Chen, Bo-Bin, Lin, Zhi-Guang, Ma, Yan, Ding, Tian-Ling, Wang, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039052/ https://www.ncbi.nlm.nih.gov/pubmed/32194707 http://dx.doi.org/10.3892/ol.2020.11328

Ejemplares similares

First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study
por: Zhong, Kaili, et al.
Publicado: (2023)

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial
por: Wu, Jingjing, et al.
Publicado: (2018)

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
por: Fan, Ni, et al.
Publicado: (2017)

MiR-181b sensitizes glioma cells to teniposide by targeting MDM2
por: Sun, Yan-chang, et al.
Publicado: (2014)

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

High‐dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma
por: Akiyama, Hiroki, et al.
Publicado: (2016)

High‐dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China
por: Chen, Cui, et al.
Publicado: (2019)

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma
por: Lee, Bryan S., et al.
Publicado: (2014)

Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma
por: Song, Kyung Mee, et al.
Publicado: (2018)

Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma
por: Fujimoto, Kenji, et al.
Publicado: (2020)

Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma
por: Bernard, S., et al.
Publicado: (2021)

Primary Central Nervous System T-cell Lymphoma as Methotrexate-associated Lymphoproliferative Disorders: Case Report
por: KAWANO, Hiroto, et al.
Publicado: (2021)

A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma
por: Villanueva, Gabriela, et al.
Publicado: (2023)

Primary Central Nervous System Lymphoma
por: Dong, Yan-Hong, et al.
Publicado: (2016)

Current and emerging therapies for primary central nervous system lymphoma
por: Yuan, Yan, et al.
Publicado: (2021)

Patients treatment with neuroglioma by teniposide and semustine and its influence on Twist and E-cadherin expression
por: Zhang, Yongbo, et al.
Publicado: (2016)

Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma: Erratum
Publicado: (2014)

Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells
por: Takashima, Yasuo, et al.
Publicado: (2019)

Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy
por: Luo, Qian, et al.
Publicado: (2021)

Cerebrospinal fluid metabolic markers predict prognosis behavior of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment
por: Zhou, Liying, et al.
Publicado: (2022)

Combined Modality Treatment Including Methotrexate-Based Chemotherapy For Primary CENTRAL Nervous System Lymphoma: A Single Institution Experience
por: Hohaus, Stefan, et al.
Publicado: (2009)

Factors Influencing the Response to High Dose Methotrexate-based Vincristine and Procarbazine Combination Chemotherapy for Primary Central Nervous System Lymphoma
por: Sung, Kang Hyun, et al.
Publicado: (2011)

Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.
por: Toffoli, G., et al.
Publicado: (1997)

Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report
por: Shimada, Hiromi, et al.
Publicado: (2015)

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
por: Suleman, Adam, et al.
Publicado: (2022)

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Shen, Haorui, et al.
Publicado: (2023)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

ML-04 The influence of surgical intervention for high-dose Methotrexate chemotherapy in the patients with primary central nervous system lymphoma
por: Okamoto, Michinari, et al.
Publicado: (2020)

Evaluation and Application of Population Pharmacokinetic Models for Identifying Delayed Methotrexate Elimination in Patients With Primary Central Nervous System Lymphoma
por: Mao, Junjun, et al.
Publicado: (2022)

LBSUN178 Teniposide Improves Adeno-associated Virus-mediated Insulin Gene Therapy In Diabetic Mice.
por: Akcan, Tugce, et al.
Publicado: (2022)

Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma
por: Li, Jinzhong, et al.
Publicado: (2006)

Preoperative blood testing for glioblastoma, brain metastases, and primary central nervous system lymphoma differentiation
por: Wang, Song-Quan, et al.
Publicado: (2022)

Relapsed Primary Central Nervous System Lymphoma: Current Advances
por: Tao, Kaiyan, et al.
Publicado: (2021)

Preliminary clinical application of multimodal imaging combined with frameless robotic stereotactic biopsy in the diagnosis of primary central nervous system lymphoma
por: Tang, Yong, et al.
Publicado: (2022)

Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort
por: Cobert, Julien, et al.
Publicado: (2009)

Urine volume to hydration volume ratio is associated with pharmacokinetics of high‐dose methotrexate in patients with primary central nervous system lymphoma
por: Isono, Tetsuichiro, et al.
Publicado: (2021)

P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
por: Tang, Y.
Publicado: (2022)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
por: Teng, Yue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q6u2dtg3ehqjv3q555nc5l37jb